The January 1, 2012, article by Chawla et al, entitled “Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas,” (Journal of Clinical Oncology 30:78-84), was published with an error of omission.
The article should have included the clinicaltrials.gov registration number (NCT number).
The line just above the Author’s Disclosures was given as: Clinical trial information can be found for the following: NCT00112372.
Instead, the line just above the Author’s Disclosures section should read: Clinical trial information can be found for the following: NCT00112372 and NCT00093080.
The online version has been corrected in departure from the print. Production regrets the omission.